Thursday, September 18, 2025 9:27:12 AM
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
So Wugen will be able to resume payments and retain the licensed molecules, provided it fulfills its obligations by the end of the suspension period.... a small light at the end of the tunnel... at least it seems like it
So Wugen will be able to resume payments and retain the licensed molecules, provided it fulfills its obligations by the end of the suspension period.... a small light at the end of the tunnel... at least it seems like it
Recent HCWB News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:12:29 PM
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/31/2026 09:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:00:07 PM
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic • GlobeNewswire Inc. • 03/17/2026 11:50:00 AM
- HCW Biologics highlights positive findings for CAR-T therapy manufacturing • IH Market News • 03/16/2026 02:31:28 PM
- HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:08:36 PM
- HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:43:57 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/19/2026 08:46:38 PM
- HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 02/18/2026 02:50:56 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/17/2026 02:09:25 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:38:42 PM
- HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune • GlobeNewswire Inc. • 02/13/2026 01:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 10:27:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/30/2026 05:15:19 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/09/2026 09:49:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 05:36:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:30:26 PM
- HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 12:30:26 PM
- HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease • GlobeNewswire Inc. • 11/18/2025 12:25:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:52:53 PM
